How should resource-poor regions develop the biopharmaceutical industry?

With regard to the development of biopharmaceutical industry, developed regions need not say much, but for the economically underdeveloped regions, but also very much want to lay out the biopharmaceutical industry in the region, how to develop has become a difficult matter.
to solve this problem, we may wish to explore the development strategies of the less developed regions today.
first we have to go back to the key point of the problem to do a thinking, lack of resources, what is lack of resources? If we comb the factor resources of the development industry, we will get the following one of the resource elements map: Figure 1: Industrial resources elements Picture source: Firestone creation For the park, these six industrial development factor resources, may lack several of them, but also will have their own resource advantages.
as an old Chinese saying: eat mountains by mountains, water by water.
for different types of resource scarcity, development-appropriate segments will vary from place to place.
E.g., for a city that has little vaccine base, no human resources and laboratory resources, it will be very difficult to develop the vaccine industry, but the city must also have its own characteristics, can match the appropriate sub-sectors, but need to find a breakthrough in the development of that field, you can develop this industry.
paths and policy approaches are specific to the system? The author thinks that the following three strategies can be explored in view of the lack of different resources.
01 With the help of MAH system, from the industrialization to attract CDMO / CMO enterprise MAH system core is to separate drug market licensing from drug production license, allowing pharmaceutical manufacturers, research and development institutions or scientific research personnel to become independent drug listing license holding, MAH system is the greatest significance is to allow the pharmaceutical market elements to flow flexibly, through the commission to authorize other production enterprises to produce or sell business enterprises to sell.
This is a change that touches on the essence of drug rights holding, the introduction of the MAH system will enable the core rights and interests of drugs to be further clarified at the legal level, the future of China's pharmaceutical ecological environment under the research and development, production and marketing of various fields of enterprise production relations and market structure will be greatly changed.
Because MAH has realized the separation of ownership and production, it has greatly stimulated the enthusiasm of research and development personnel, and the impact on pharmaceutical research and development outsourcing (CRO) is particularly significant, and the person (the holder of the drug listing license document) has the right to produce drugs on his own or entrusted to other pharmaceutical production enterprises, and to bear the main legal responsibility for the quality of the drugs produced and sold.
through the MAH system, resource-poor areas, through the introduction of production types of CMO / CDMO enterprises, to become the national production base of biological drugs.
in the construction of production base and constantly improve the situation, and gradually accumulate biopharmaceutical industry resources.
meet the requirements of achieving results in the short term, but also can accumulate industrial factor resources in the long term.
, in the system needs to focus on the characteristics of CMO enterprises, design the corresponding industrial support policies, so that CMO / CDMO enterprises are willing to land to the local.
figure 2: CDMO in the pharmaceutical research and development production stage Photo source: Firestone to create 02 smart use of industry guidance funds, mergers and acquisitions in order to develop the local economy, the current common practice is to set up local industrial investment companies or parent fund companies, give full play to the government-led, market-oriented operation of the resource allocation capacity advantages, accelerate economic development.
On the other hand, of the nearly 100 location-selection enterprises we have come into contact with, the vast majority of pharmaceutical and health enterprises expect to be supported by local government industrial funds;
With the consistent evaluation, the deepening of the implementation of the "4 plus 7" volume procurement, the policy led to a major reshuffle of the industry, a large number of small and medium-sized enterprises may face survival problems, such as the lack of competitiveness of some varieties, the market gradually shrinking leading to overcapacity, or some enterprises have access to greater market opportunities, the need to expand production capacity and supplement product lines.
Local governments can seize this opportunity to give full play to the advantages of resource allocation, through investment and mergers and acquisitions, to promote local enterprises or enterprises with the ability to mergers and acquisitions, through government-led investment and mergers and acquisitions, will have a competitive advantage of the enterprise part of the business into the local to achieve investment.
figure 3: 2019 Biopharmaceutical mergers and acquisitions listed plate distribution Picture: Firestone Created 03 to take advantage of location to develop the pharmaceutical trade industry By the end of 2020, the number of high-speed rail journeys operated in China is expected to exceed 3.5 kilometers, covering 31 provincial administrative regions (including Hong Kong), the number of high-speed rail stations has reached more than 500.
especially in the last two years of new high-speed rail stations, there is no shortage of the central and western regions and other revolutionary old areas and underdeveloped areas, typical of jiangxi Ganzhou Xingguo County, Shandong Linyi, Anhui Puyang, Guizhou Bi Festival ... For the first time, these familiar old revolutionary areas and poor areas have access to high-speed rail networks.
addition to high-speed rail, there is a highway network, by the end of 2019, China's highways have more than 149,600 kilometers, ranking first in the world.
biopharmaceutical industry is a typical "three high" industry, not every park is suitable to start from the research and development side, the circulation of pharmaceutical trade is also an important part of the whole industry.
In present, with the two-vote system, "4 plus 7" with the volume of procurement and other policies landing, coupled with the future of some biological drugs need to be transported through a better cold chain, so some pharmaceutical circulation enterprises will also warehouse base in accordance with the regional layout.
park with good location transportation advantages, can completely through the introduction of pharmaceutical trade circulation enterprises to develop local industries, through the creation of excellent circulation base, and gradually to industrial production and manufacturing upstream derivatives, which is also a path of industrial development.
figure 4: Pharmaceutical circulation industry sales and circulation mode Data sources: Firestone creation according to public information finishing At present, many domestic pharmaceutical enterprises have been in the pharmaceutical logistics platform, cold storage / information platform and other pharmaceutical cold chain infrastructure investment, such as China National Pharmaceutical Holdings in Shanghai to establish a large logistics center, Kyusju Tong in Wuhan to build the world's largest single pharmaceutical logistics center.
with the opening of electronic prescriptions, the pharmaceutical e-commerce industry will be rapid development, the future in the C-side logistics will also be one of the huge market.
Summary Resource scarcity is relative, find suitable industrial positioning and suitable for the local special sub-areas, combined with the characteristics of regional factors and resources, resource-poor areas still have the opportunity to develop the biopharmaceutical industry, to achieve the replacement of oversized vehicles.